Compare AstraZeneca plc (AZN) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Mattel Inc — how do they compare? AstraZeneca plc trades at $158.91 (market cap $250.84B), while Mattel Inc trades at $15.05 (market cap $4.21B). The key difference: AstraZeneca plc is far larger — about 59.6× Mattel Inc's market cap, and AstraZeneca plc pays a 1.97% dividend while Mattel Inc pays none. Which is the better fit depends on your goals.
| AZN | MAT | |
|---|---|---|
Market Cap | $250.84B | $4.21B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $22.16 |
52-Week Low | $147.06 | $13.05 |
Enterprise Value | $278.12B | $6.44B |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).
The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.
Mattel (MAT) trades at $14.79, up 2.07% with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results with revenue growth of 10% but an earnings miss due to higher costs. Valuation appears reasonable with P/E of 11.03 and P/S of 0.82, while profitability metrics show strong ROE of 20.5% despite margin pressures from increased advertising expenses.
The stock presents a balanced opportunity with analyst consensus leaning bullish (53% buy ratings) but faces near-term headwinds from cost inflation and discretionary spending pressures. Long-term growth drivers include toy-based entertainment partnerships and digital gaming expansion, though execution risks and market volatility require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
